Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 84

1.

Frontal brain activity and cognitive processing speed in multiple sclerosis: An exploration of EEG neurofeedback training.

Keune PM, Hansen S, Sauder T, Jaruszowic S, Kehm C, Keune J, Weber E, Schönenberg M, Oschmann P.

Neuroimage Clin. 2019 Feb 11;22:101716. doi: 10.1016/j.nicl.2019.101716. [Epub ahead of print]

2.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170.

PMID:
29576505
3.

Exploring resting-state EEG brain oscillatory activity in relation to cognitive functioning in multiple sclerosis.

Keune PM, Hansen S, Weber E, Zapf F, Habich J, Muenssinger J, Wolf S, Schönenberg M, Oschmann P.

Clin Neurophysiol. 2017 Sep;128(9):1746-1754. doi: 10.1016/j.clinph.2017.06.253. Epub 2017 Jul 14.

PMID:
28772244
4.

Measuring standing balance in multiple sclerosis: Further progress towards an automatic and reliable method in clinical practice.

Keune PM, Young WR, Paraskevopoulos IT, Hansen S, Muenssinger J, Oschmann P, Müller R.

J Neurol Sci. 2017 Aug 15;379:157-162. doi: 10.1016/j.jns.2017.06.007. Epub 2017 Jun 8.

PMID:
28716231
5.

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group.

Ann Neurol. 2017 Jul;82(1):20-29. doi: 10.1002/ana.24965.

6.

[Telemedicine: Comprehensive coverage and quality - Not a contradiction : Practical experience from the stroke network with telemedicine in northern Bavaria (STENO)].

Breuer L, Erbguth F, Oschmann P, Schwab S.

Nervenarzt. 2017 Feb;88(2):130-140. doi: 10.1007/s00115-016-0264-0. German.

PMID:
28083685
7.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

8.

Cognitive screening in Multiple Sclerosis: the Five-Point Test as a substitute for the PASAT in measuring executive function.

Hansen S, Muenssinger J, Kronhofmann S, Lautenbacher S, Oschmann P, Keune PM.

Clin Neuropsychol. 2017 Jan;31(1):179-192. doi: 10.1080/13854046.2016.1241894. Epub 2016 Oct 6.

PMID:
27707354
9.

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.

10.

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.

O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas.

Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10. Erratum in: Neurology. 2016 Oct 4;87(14 ):1524.

11.

Cognitive screening tools in multiple sclerosis revisited: sensitivity and specificity of a short version of Rao's Brief Repeatable Battery.

Hansen S, Muenssinger J, Kronhofmann S, Lautenbacher S, Oschmann P, Keune PM.

BMC Neurol. 2015 Nov 26;15:246. doi: 10.1186/s12883-015-0497-8.

12.

Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).

Keune PM, Cocks AJ, Young WR, Burschka JM, Hansen S, Hofstadt-van Oy U, Oschmann P, Muenssinger J.

BMC Neurol. 2015 Sep 24;15:171. doi: 10.1186/s12883-015-0431-0.

13.

Brain magnetic resonance imaging findings fail to suspect Fabry disease in young patients with an acute cerebrovascular event.

Fazekas F, Enzinger C, Schmidt R, Grittner U, Giese AK, Hennerici MG, Huber R, Jungehulsing GJ, Kaps M, Kessler C, Martus P, Putaala J, Ropele S, Tanislav C, Tatlisumak T, Thijs V, von Sarnowski B, Norrving B, Rolfs A; SIFAP 1 Investigators.

Stroke. 2015 Jun;46(6):1548-53. doi: 10.1161/STROKEAHA.114.008548. Epub 2015 Apr 21.

PMID:
25899239
14.

Use of a telestroke service for evaluation of non-stroke neurological cases.

Handschu R, Wacker A, Scibor M, Sancu C, Schwab S, Erbguth F, Oschmann P, Stark D, Marquardt L.

J Neurol. 2015 May;262(5):1266-70. doi: 10.1007/s00415-015-7702-y. Epub 2015 Mar 21.

PMID:
25794862
15.

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.

Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT; CONFIRM study investigators.

Neurology. 2015 Mar 17;84(11):1145-52. doi: 10.1212/WNL.0000000000001360. Epub 2015 Feb 13.

16.

Mindfulness-based interventions in multiple sclerosis: beneficial effects of Tai Chi on balance, coordination, fatigue and depression.

Burschka JM, Keune PM, Oy UH, Oschmann P, Kuhn P.

BMC Neurol. 2014 Aug 23;14:165. doi: 10.1186/s12883-014-0165-4.

17.

Feasibility of certified quality management in a comprehensive stroke care network using telemedicine: STENO project.

Handschu R, Scibor M, Wacker A, Stark DR, Köhrmann M, Erbguth F, Oschmann P, Schwab S, Marquardt L.

Int J Stroke. 2014 Dec;9(8):1011-6. doi: 10.1111/ijs.12342. Epub 2014 Aug 4.

PMID:
25088571
18.

Normative data and long-term test-retest reliability of the triple stimulation technique (TST) in multiple sclerosis.

Hofstadt-van Oy U, Keune PM, Muenssinger J, Hagenburger D, Oschmann P.

Clin Neurophysiol. 2015 Feb;126(2):356-64. doi: 10.1016/j.clinph.2014.05.032. Epub 2014 Jun 21.

PMID:
25027641
19.

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators.

Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30.

PMID:
24794721
20.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.

Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G; SELECTION Study Investigators.

Lancet Neurol. 2014 May;13(5):472-81. doi: 10.1016/S1474-4422(14)70039-0. Epub 2014 Mar 19.

PMID:
24656609

Supplemental Content

Loading ...
Support Center